AVX 0.00% 2.5¢ avexa limited

avx hiv integrase has us$1bn sales potential

  1. 4,608 Posts.
    lightbulb Created with Sketch. 235
    "Data from the clinical trial also showed that ATC
    was especially effective when used with two existing marketed HIV drugs."

    HIV integrase:

    Since the approval of Merck’s raltegravir (Isentress®), which targets HIV integrase, this drug has been widely
    prescribed and has demonstrated itself to be a most effective therapy for HIV infections in combination with an
    optimised background regimen. In 2010 Isentress® generated global revenues of around US$1Bn.

    "Avexa has discovered a number of novel compound classes with activity superior to raltegravir against wild
    type HIV-1. Moreover, these compounds are highly potent against raltegravir- and elvitegravir-resistant

watchlist Created with Sketch. Add AVX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.